LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Strona główna・Stock List・Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings Inc (Class A)

Closed

SectorHealthcare

4.72 -2.28

Buy Sell

Overview

Share price change

24h

Current

Min

4.59

Max

4.99

Key metrics
By Trading Economics
Income	-15M -40M
Sales	8.2M 50M
Profit margin	-80.43
Employees	435
EBITDA	-19M -42M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	-7.42% downside

Market Stats
By TradingEconomics
Market Cap	277M 1.4B
Previous open	7
Previous close	4.72

News Sentiment

By Acuity

50%

175 / 346 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

2.02 / 2.115 Support & Resistance

Maravai LifeSciences Holdings Inc (Class A) Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 maj 2026, 22:15 UTC

Acquisitions, Mergers, Takeovers

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 maj 2026, 23:46 UTC

Market Talk

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 maj 2026, 23:44 UTC

Market Talk

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 maj 2026, 23:33 UTC

Market Talk

Gold Rises on Possible Position Adjustments -- Market Talk

11 maj 2026, 22:37 UTC

Market Talk

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 maj 2026, 22:32 UTC

Earnings

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 maj 2026, 22:02 UTC

Market Talk

Major News Events

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 maj 2026, 21:49 UTC

Earnings

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 maj 2026, 21:42 UTC

Market Talk

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 maj 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 maj 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 maj 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 maj 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 maj 2026, 21:31 UTC

Acquisitions, Mergers, Takeovers

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 maj 2026, 21:23 UTC

Acquisitions, Mergers, Takeovers

CSG Systems Sale to NEC Gets CFIUS Clearance

11 maj 2026, 21:12 UTC

Earnings

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 maj 2026, 21:12 UTC

Earnings

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 maj 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

11 maj 2026, 20:44 UTC

Earnings

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 maj 2026, 20:43 UTC

Earnings

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 maj 2026, 20:32 UTC

Earnings

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 maj 2026, 20:32 UTC

Earnings

CleanSpark 2Q Rev $136.4M >CLSK

11 maj 2026, 20:30 UTC

Earnings

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 maj 2026, 20:30 UTC

Earnings

Steris 4Q Cont Ops EPS $2.24 >STE

11 maj 2026, 20:30 UTC

Earnings

Steris 4Q Rev $1.6B >STE

11 maj 2026, 20:30 UTC

Earnings

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 maj 2026, 20:30 UTC

Earnings

Steris 4Q Adj EPS $2.83 >STE

11 maj 2026, 20:22 UTC

Hot Stocks

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 maj 2026, 19:37 UTC

Earnings

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 maj 2026, 19:32 UTC

Market Talk

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Peer Comparison

Price change

Maravai LifeSciences Holdings Inc (Class A) Forecast

Price Target

By TipRanks

-7.42% downside

12 Months Forecast

Average 4.49 USD -7.42%

High 6 USD

Low 3 USD

Based on 7 Wall Street analysts offering 12 month price targets forMaravai LifeSciences Holdings Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Maravai LifeSciences Holdings Inc (Class A) - Dist in the past 3 months.

Technical Score

By Trading Central

2.02 / 2.115Support & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There are no events.

Sentiment

By Acuity

175 / 346 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.